Eris Lifesciences540596Quarterly results
Board approves Q2/H1 FY2026 results; unmodified limited review; scheme of arrangement effective
Board approved unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026.
By ScoutQuest · · 3 min read
| Line item | Latest | Year ago | YoY | Prev qtr | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 892.37 | 792.41 | +12.6% | 873.25 | +2.2% |
| Total income | 895.57 | 795.22 | +12.6% | 875.64 | +2.3% |
| Profit before tax | 155.91 | 172.67 | −9.7% | 179.49 | −13.1% |
| Profit after tax | 187.14 | 134.47 | +39.2% | 143.32 | +30.6% |
| Total comprehensive income | 185.98 | 133.90 | +38.9% | 143.38 | +29.7% |
| Basic EPS | 13.26 | 8.82 | +50.3% | 10.28 | +29% |
- Total Income YoY Growth
- +12.6% (Year ago 795.22)
- Profit After Tax (Latest)
- 187.14 (+39.2% YoY)
- Period
- September 30, 2026 (Unaudited)
Auditor's review
Conclusion: Unmodified
Notes to the results
- Exceptional item: write down of amounts due from customers of Rs. 35.90 Crore on settlement for products launched at risk in earlier periods.
- Scheme amalgamating Aprica Healthcare and demerging EOHPL's Domestic Business into Eris Therapeutics approved by NCLT on 24 September 2026, effective 22 October 2026; appointed date 1 April 2025.
- Scheme tax effect: current tax credit of Rs. 96 crores and deferred tax charge of Rs. 31 crores; goodwill adjusted for deferred tax liabilities on brand assets of Rs. 220 crores.
- Rs 17.24 Crores past service cost from New Labour Codes shown as exceptional item for year ended March 31, 2026.
Board meeting outcome
- The Board met on 26 October 2026 from 11:00 A.M. to 01:40 P.M. and approved the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026.
- The results were first recommended by the Audit Committee at its meeting held on the same date.
Auditor's review conclusion
- Walker Chandiok & Co LLP issued limited review reports on both the standalone and the consolidated results with unmodified opinion(s), that is free from any qualifications.
- A review is narrower than a full audit, so it does not express an audit opinion.
- For five subsidiaries and one joint venture, the auditor relied on the review reports of other auditors; those entities reflect total assets of ₹ 1,474.07 Crores as at 30 September 2026 and total revenues of ₹ 163.96 Crores and ₹ 275.14 Crores for the quarter and six-month period.
Headline numbers (consolidated, Rupees in Crore)
- Net profit after tax: 187.14 for the quarter and 330.46 for the half year, against 134.47 and 259.57 in the same periods a year earlier.
- Net profit margin: 20.97% for the quarter against 16.97% a year earlier; operating margin 26.80% against 28.01%.
- Net worth: 4,141.57 as at 30 September 2026.
- Earnings per share (basic): 13.26 for the quarter; diluted 13.25.
- Debt-equity ratio: 0.59 times; interest service coverage ratio 5.15 times.
- Net cash generated from operating activities: 697.13 for the half year, against 239.05 a year earlier. Cash and cash equivalents at the end of the period: 238.09.
Items that shaped the numbers
- An exceptional item of Rs. 35.90 Crore was recognised - a write down of amounts due from customers, net of collections and past provisions, as part of a settlement for products supplied in earlier periods.
- The new labour codes, effective 21 November 2025, raised gratuity and leave liability from past service cost by Rs 17.24 Crores, presented as an exceptional item for the year ended March 31, 2026.
- The scheme of arrangement produced a current tax credit of Rs. 96 crores and a deferred tax charge of Rs. 31 crores in the consolidated results for the period ended 30 September 2026.
Scheme of arrangement
- Aprica Healthcare Limited was amalgamated, and the Domestic Business of Eris Oaknet Healthcare Private Limited was demerged, into Eris Therapeutics Limited.
- The National Company Law Tribunal approved the scheme by order dated 24 September 2026, with an appointed date of 1 April 2025; it became effective on 22 October 2026 on update with the Registrar of Companies.
- Business losses of Eris Oaknet Healthcare can now be set off against the business profits of Eris Therapeutics, and amortisation of brand assets became tax deductible with effect from the appointed date.
- Goodwill in the consolidated financial statements was adjusted for deferred tax liabilities on brand assets amounting to Rs. 220 crores as on the appointed date.
Other points to note
- 1,95,682 ordinary shares of Rs 1 each were issued and allotted under the Employee Stock Option Scheme 2021 during the half year ended September 30, 2026.
- The acquisition of the Branded Probiotics Business from Velbion Probiotics Private Limited, for a consideration of Rs 50 Crores on a slump sale basis, was completed on March 31, 2026; the final fair value determination for the purchase price allocation is in process.
- The company operates in a single business segment, Pharmaceuticals.
Summing up
Profit after tax rose year on year for both the quarter and the half year, helped by the tax credit from the scheme, while the exceptional write down and the labour code charge sit alongside it. The auditor's conclusion on the results is unmodified.
873.25 (Rs in Crore)Revenue from operations, quarter
Net profit after tax, consolidated, quarter ended Sep 30, (Rs in crore₹187.14 Cr
Profit after tax, latest quarter187.14 (Rs in Crore)
Profit before tax, quarter179.49 (Rs in Crore)
Profit before tax, year-ago quarter172.67 (Rs in Crore)
Profit after tax, quarter143.32 (Rs in Crore)
Also from Eris Lifesciences
Eris Lifesciences posts Q2 FY27 earnings call recording held on October 26, 2026
26 Oct 2026
Eris Lifesciences Q2 FY27: revenue up 12.6% to Rs. 892 cr, PAT up 39.2%; gross margin levers from Zorvia out-licensing and Bhopal insulin shift
26 Oct 2026
Eris Lifesciences schedules Q2 & H1 FY2027 earnings call for October 26, 2026 at 4:30 PM IST
19 Oct 2026
More numbers
- Net profit margin, consolidated, quarter ended Sep 30, 202620.97%
- Net worth, consolidated (Rs in crore)4,141.57
- Exceptional item: write down of amounts due from customersRs. 35.90 Crore
- Additional gratuity and leave liability from new labour codesRs 17.24 Crores
- Current tax credit from the scheme of arrangementRs. 96 crores
- Deferred tax charge from the scheme of arrangementRs. 31 crores
- Ordinary shares allotted under ESOS 2021 during the half year1,95,682
- Total income, latest quarter895.57 (Rs in Crore)
- Total income, year-ago quarter795.22 (Rs in Crore)
- Total income, previous quarter875.64 (Rs in Crore)
- Total comprehensive income, latest quarter185.98 (Rs in Crore)
- Total comprehensive income, year-ago quarter133.90 (Rs in Crore)
- Total comprehensive income, previous quarter143.38 (Rs in Crore)
- Profit after tax, latest quarter187.14 (Rs in Crore)
- Profit after tax, year-ago quarter134.47 (Rs in Crore)
- Profit after tax, previous quarter143.32 (Rs in Crore)
- Revenue from operations, latest quarter892.37 (Rs in Crore)
- Revenue from operations, year-ago quarter792.41 (Rs in Crore)
- Revenue from operations, previous quarter873.25 (Rs in Crore)
- Profit before tax, latest quarter155.91 (Rs in Crore)
- Profit before tax, year-ago quarter172.67 (Rs in Crore)
- Profit before tax, previous quarter179.49 (Rs in Crore)
Source: BSE · 26 Oct 2026
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.